Close menu




November 12th, 2019 | 06:36 CET

AURORA, BEVCANNA, CANOPY OR EXMCEUTICALS - WHICH CANNABIS SHARE HAS POTENTIAL?

  • Cannabis
Photo credits: pixabay.com

The shares of Canadian cannabis companies have lost significant value this year. There are exceptions, such as BevCanna and EXMceuticals, but the well-known players such as Aurora and Canopy have fallen significantly. This was preceded by a period of price rises and forecasts that never seemed to end. In the meantime, the phase of speculation is over and it is all about facts. Speculators go out and investors stand on the sidelines and observe the development or already use the chance to enter.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA05156X1087

Table of contents:


    Philip Schetter, CEO, Cantourage Group SE
    "[...] We are a producer and distributor of medicinal products and thus cover a crucial step in the value chain, especially within the cannabis industry. [...]" Philip Schetter, CEO, Cantourage Group SE

    Full interview

     

    AURORA SHARE LOST MORE THAN 60%.

    The shares of Aurora and Canopy have lost significant value this year. The shares of Aurora changed hands this year at the top of the Canadian home stock exchange at CAD 13.67. The shares of Aurora have lost a lot of value this year. On yesterday's trading day, the stock was sold at 4.78 CAD. The low for the year so far was 4.58 CAD. At the peak of the hype in 2018, the share was still listed at CAD 16.74. The current market value is CAD 4.88 billion.

    WHEN WAS THE BOTTOM FOUND AT CANOPY?

    The development is similar for the industry giant Canopy. The company's shares peak in 2019 at 70.99 CAD. In the previous year even a price of 76.68 CAD was reached. Size also does not protect this title from a price correction and in the meantime the share is listed close to the low for the year of 25.00 CAD. Yesterday, the share was sold at 26.85 CAD. Canopy's market value has thus shrunk to CAD 9.35 billion.

    STOCK EXCHANGE DEBUTANTS OFFER ALTERNATIVE

    Meanwhile, the situation at BevCanna and EXMceuticals looks more relaxed, but this is certainly also due to the size of the two companies. BevCanna is a producer of cannabis drinks and, like CBD producer EXMceuticals, celebrated its stock market debut this year. The two companies were thus spared the hype in 2018 and the share price trend is thus calmer - without massive setbacks. The company value of BevCanna amounts to about 20.93 million CAD with a share price of 0.44 CAD.

    At yesterday's closing price of CAD 1.00, EXMceuticals reported a stock market value of CAD 36.55. The company's share price was around CAD 20.93 million. Jonathan Summers is Chairman of EXMceuticals and will present the company to investors at this year's German Equity Forum of Deutsche Börse AG in Frankfurt from 25 to 27 November 2019.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on October 11th, 2023 | 07:50 CEST

    New iPhone moment? Apple, NVIDIA, Cantourage

    • Software
    • Innovations
    • Cannabis
    • Technology

    On January 9, 2007, the world changed. That was when Apple introduced its iPhone. Smartphones with touchscreens were previously unknown, but today? Hardly anyone can do without smartphones, tablets and the like! For Apple, the iPhone was the product that changed many things and made the Californians the most valuable company in the world for a time. At the end of 2022, ChatGPT was the next technology to change the world. NVIDIA's stock has been soaring ever since. We highlight NVIDIA and Apple and examine what revolution could change everything for the German company Cantourage.

    Read

    Commented by Juliane Zielonka on October 6th, 2023 | 08:00 CEST

    Cantourage Group SE, Amazon, British American Tobacco: Stockpiling between medical innovation and dividend history

    • Cannabis
    • Healthcare
    • AI

    The Berlin-based company Cantourage, which specializes in the distribution of medical cannabis, is experiencing promising growth in the booming medical cannabis market. The global market for the plant's medical use is expected to have reached around USD 12.92 billion since 2021 and is projected to grow to USD 23.97 billion by 2028 at an average CAGR of 13.16%. Cantourage continues to expand its strong international distribution network with its innovative Fast Track Access platform. The Company even has a chance to win in the "Most Innovative Business Strategy" category at the 2023 European Small and Midcap Awards in November. Unlike other medical cannabis producers, Cantourage does not grow its own plants. Just as Uber doesn't own cars and AirBnB doesn't own hotels, Cantourage relies on strong distribution power in Healthcare. Healthcare is also attractive to Amazon again. Through mergers and acquisitions involving an online pharmacy and a thriving network of doctors, the US company is now investing in generative AI beyond ChatGPT. Meanwhile, historic dividend king British American Tobacco faces decline and bans.

    Read

    Commented by Armin Schulz on September 20th, 2023 | 08:25 CEST

    Canopy Growth, Cantourage Group, Aurora Cannabis - Will the price fireworks come after legalization?

    • Cannabis

    For a long time, there was little reason for cannabis investors to rejoice. However, since Bloomberg reported that the US Department of Health and Human Services has asked the DEA to downgrade cannabis from Schedule 1 to Schedule 3, hopes for legalization are reviving. This downgrade would mean that cannabis would no longer be on par with heroin or other hard drugs. Democrats also want to give businesses in this sector legal access to bank accounts. In Germany, the traffic lights have approved Health Minister Lauterbach's plans to legalize cannabis. We, therefore, look at three companies that are betting on cannabis.

    Read